Evidence map›Paper›PMID 31957304›Full record

ArticleCPT: pharmacometrics & systems pharmacology2020

gQSPSim: A SimBiology-Based GUI for Standardized QSP Model Development and Application.

Iraj Hosseini, Justin Feigelman, Anita Gajjala, Monica Susilo, Vidya Ramakrishnan, Saroja Ramanujan, Kapil Gadkar

Open access · goldAbstract read
In one paragraph

Article in CPT: pharmacometrics & systems pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Model-informed drug discovery and development approaches to inform clinical trial design and regulatory decisions: A primer for the MENA region.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024
    Review
  5. Article
  6. Towards a comprehensive assessment of QSP models: what would it take?Journal of pharmacokinetics and pharmacodynamics · 2024
    Review
  7. "Digital twins elucidate critical role of TNPJ systems biology and applications · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Evaluation framework for systems models.CPT: pharmacometrics & systems pharmacology · 2022
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Iraj HosseiniGenentech Inc., South San Francisco, California, USA.
Justin FeigelmanGenentech Inc., South San Francisco, California, USA.
Anita GajjalaConsulting Services, MathWorks, Natick, Massachusetts, USA.
Monica SusiloGenentech Inc., South San Francisco, California, USA.
Vidya RamakrishnanGenentech Inc., South San Francisco, California, USA.
Saroja RamanujanGenentech Inc., South San Francisco, California, USA.
Kapil GadkarGenentech Inc., South San Francisco, California, USA.
MathWorks (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Quantitative systems pharmacology (QSP) models are often implemented using a wide variety of technical workflows and methodologies. To facilitate reproducibility, transparency, portability, and reuse for QSP models, we have developed gQSPSim, a graphical user interface-based MATLAB application that performs key steps in QSP model development and analyses. The capabilities of gQSPSim include (i) model calibration using global and local optimization methods, (ii) development of virtual subjects to explore variability and uncertainty in the represented biology, and (iii) simulations of virtual populations for different interventions. gQSPSim works with SimBiology-built models using components such as species, doses, variants, and rules. All functionalities are equipped with an interactive visualization interface and the ability to generate presentation-ready figures. In addition, standardized gQSPSim sessions can be shared and saved for future extension and reuse. In this work, we demonstrate gQSPSim's capabilities with a standard target-mediated drug disposition model and a published model of anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) treatment of hypercholesterolemia.

Indexed as

Antibodies, Monoclonal, HumanizedComputer SimulationDrug DevelopmentDrug DiscoveryHumansHypercholesterolemiaModels, BiologicalPCSK9 InhibitorsProprotein Convertase 9Reference StandardsReproducibility of ResultsSoftwareUncertaintyUser-Computer InterfaceWorkflowAntibodies, Monoclonal, HumanizedPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9

Identifiers

PMID31957304
PMCPMC7080534
OpenAlexW3001602688

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.